Med. Pro Praxi 2009; 6(1): 34-37

Antibiotic therapy of respiratory infections

MUDr. Václava Bártů
Pneumologická klinika, Fakultní Thomayerova nemocnice a 1. lékařská fakulta UK, Praha

Upper and low respiratory tract infections belong among the most frequent diseases of childhood and adults. Although many of them are

of viral aetiology, they are treated by antibiotics. But it is necessary the use of antibiotics reserves for bacterial infections. Knowledge of

local bacteriological situation of workplace, local drug resistance, national and international recommendations for therapy of respiratory

diseases play important role in the choice of the optimal antibiotic drug. The basis requirement for select drug is its efficiency, safety

and quality in the clinical practice which leads to the suppression of the bacterial infection. The initial empiric therapy can be changed

in the case if the bacterial origin of the disease is documented into the rational therapy based on the drug sensitivity tests. Increasing

use of antibiotics is directly followed by increasing bacterial resistance. Unsubstantiated antibiotic therapy in the bad-founded cases

makes the situation wrong and it leads to the decreasing antibiotic efficiency. This strategy increases costs of the effective treatment

of respiratory infections. Detailed knowledge of effective spectrum, mechanism of drug penetration into the infection place, local epidemiological

situation form the basis presumptions for the optimal antibiotic choice. National and international standards provide the

specific recommendations for therapy of respiratory infections.

Keywords: antibiotics, respiratory infections, clinical efficiency, resistance.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bártů V. Antibiotic therapy of respiratory infections. Med. praxi. 2009;6(1):34-37.
Download citation

References

  1. Sechser T. Současné možnosti hodnocení účinnosti léčiv v běžné klinické praxi. Čes.-slov. Pediat. 2004? 59: 536-538.
  2. Kanwar M, Brar N, Khatib R, Fakih M. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics. Chest 2007; 131: 1865-1869. Go to original source... Go to PubMed...
  3. Niederman MS. Recent advances in community acquired pneumonia. Chest 2007; 131: 1205-1215. Go to original source... Go to PubMed...
  4. Marešová V. Nejčastější chyby a omyly v antibiotické terapii dýchacích cest. Pediatr. pro Praxi 2003? 76: 307-311.
  5. Metersky ML, Sweeney TA, Getzow MB, et al. Antibiotic timing and diagnostic uncertainty in medicare patients with pneumonia. Chest 2006? 130: 16-21. Go to original source... Go to PubMed...
  6. Kolek V. Léčba komunitní pneumonie. Medicína po promoci 2004? 5: 46-50.
  7. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections. Drug 2003? 63: 2157-2168. Go to original source... Go to PubMed...
  8. Urbášková P. Surveillance antibiotické rezistence. Lékařské listy 2003? 21: 31-33.
  9. Hirschmann JV. Antibiotika při běžných infekcích dýchacího ústrojí u dospělých. Jama-CS 2002? 10: 752-758.
  10. Blasi F. The pathogenesis of community-acquired pneumonia. Eur Respir Rev 2004? 13: 60-84.
  11. Kolář M. Antibiotická léčba zánětu plic. Klin Farmakol Farm 2006? 20: 97-99.
  12. Kolek V. Komunitní pneumonie. Postgraduální medicína 2006? 6: 630-638.
  13. Wenzel RP, Fowler AA. Acute bronchitis. N Engl J Med 2006? 355: 2125-2130. Go to original source... Go to PubMed...
  14. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult respiratory tract infections. Eur Respir J 2005? 26: 1138-1180. Go to original source... Go to PubMed...
  15. Amsden GW, Baier IM, Simon S, Treadway G. Efficacy and safety of azithromycin vs levofloxacinin the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003? 123: 772-777. Go to original source... Go to PubMed...
  16. Restrepo MI, Anzueto A. Guidelines for the diagnose and treatment of adult lower respiratory tract infections: a true, ,European cooperative effort". Eur Respir J 2005; 26: 979-981. Go to original source... Go to PubMed...
  17. Spindler C, Örtqvist A. Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. Eur Respir. J 2006; 28: 816-823. Go to original source... Go to PubMed...
  18. Biederman MS. Clinical significance of macrolide resistence. Eur Respir Rev 2004? 13: 91-95. Go to original source...
  19. Mandell LA. Macrolides and management of community-acquired pneumonia: a review of international guidelines. Eur Respir Rev 2004? 13: 85-87.
  20. Brown RB, Iannini P, Gross P, Kukel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia. Chest 2003? 123: 1503-1510. Go to original source... Go to PubMed...
  21. Baddour LM, Yu VL, Klugman KP, et al. Combination of antibiotic therapy lowers mortality among severely ill patiens with pneumococcal bacteremia. Am J Respir Crit Care Med 2004? 170: 440-444. Go to original source... Go to PubMed...
  22. Moellering RC Jr. The continuing challenge of respiratory tract infections. Clin Infect Dis 2004? 38: 319-321. Go to original source... Go to PubMed...
  23. Yu VL, Greenberg RN, Zadeikis A, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004? 125: 2135-2139. Go to original source... Go to PubMed...
  24. Menendez R, Torres A. Treatment failure in community acquired pneumonia. Chest 2007; 132: 1348-1355. Go to original source... Go to PubMed...
  25. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community acquired pneumonia: a population-based study. Eur Respir J 2008; 31: 1274-1284. Go to original source... Go to PubMed...
  26. Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 2002? 20(Suppl. 36): 3s-8s. Go to original source... Go to PubMed...
  27. Bébrová E, Beneš J, Čížek J, et al. Doporučený postup pro antibiotickou léčbu komunitních respiračních infekcí v primární péči. Praktické lékárenství 2003? 83: 502-515.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.